Elizabeth Nguyen, MD
Nephrology · Atlanta, GANPI 1629000344
Payments from drug & device makers
Across 332 payments — averaging $1399.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vertex$194K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$160K
- Eli Lilly$63K
- Novartis$42K
- AstraZeneca$852
- Vifor Pharma, Inc.$647
- plus $5K from 25 others
Across 4 payments — averaging $6295.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$25K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$94
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vertex | 5 | $193,811 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 6 | $160,033 |
| Eli Lilly | 1 | $62,871 |
| Novartis | 19 | $42,016 |
| AstraZeneca(2 entities) | 42 | $852 |
| Vifor Pharma, Inc. | 34 | $647 |
| Bayer | 26 | $599 |
| Fresenius USA Marketing, Inc. | 42 | $542 |
| Amgen(2 entities) | 27 | $527 |
| Otsuka America Pharmaceutical, Inc. | 17 | $352 |
| Daiichi Sankyo Inc. | 17 | $320 |
| Mallinckrodt Hospital Products Inc. | 10 | $311 |
| Akebia Therapeutics Inc | 13 | $295 |
| Novo Nordisk | 7 | $263 |
| Aurinia Pharma U.S., Inc. | 9 | $239 |
| OPKO Pharmaceuticals, LLC | 14 | $228 |
| Calliditas Therapeutics US Inc. | 10 | $213 |
| GSK | 9 | $175 |
| Lilly USA, LLC | 5 | $80 |
| ANI Pharmaceuticals, Inc. | 3 | $67 |
| Alnylam Pharmaceuticals Inc. | 2 | $48 |
| Baxter Healthcare | 2 | $43 |
| Boehringer Ingelheim | 2 | $39 |
| AMAG Pharmaceuticals, Inc. | 2 | $34 |
| Sanofi | 1 | $32 |
| Pfizer | 1 | $30 |
| Ardelyx, Inc. | 1 | $23 |
| Lemaitre Vascular, Inc. | 1 | $20 |
| Genentech USA, Inc. | 1 | $19 |
| Scpharmaceuticals Inc. | 1 | $18 |
| Travere Therapeutics, Inc. | 2 | $13 |
How this compares
$464,758 in reported general payments places this provider in the 95th percentile of 388 nephrology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Atlanta
- Frederic Rahbari OskouiAtlanta$1.5M
- Stuart HandelsmanAtlanta$711K
- Sheldon ShoreAtlanta$474K
- William OneillAtlanta$281K
- Janice LeaAtlanta$241K
- Frita FisherAtlanta$220K
- Haimanot WasseAtlanta$194K
- Christina KleinAtlanta$137K
- Mary MuonekeAtlanta$119K
- Tarik LalwaniAtlanta$72K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.